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6.2 Antidepressant Medications
Amir Afkhami, MD, PhD

HISTORY
The first effective antidepressant, iproniazid phosphate—a monoamine oxidase inhibitor (MAOI)—was
originally developed to treat tuberculosis, but was observed to have antidepressant effects. It was marketed to treat
depression in 1958. Iproniazid was later replaced by imipramine—originally developed to treat psychotic disorders
in the 1950s—a less hepatotoxic drug and the first drug in the long line of tricyclic antidepressants (TCAs). The
tricyclics were followed by the more tolerated serotonin reuptake inhibitors (SSRIs), beginning with fluoxetine
hydrochloride (Prozac), which was approved for the treatment of depression in December 1987.

GENERAL FACTS AND PRINCIPLES OF DEPRESSION AND
ANTIDEPRESSANT TREATMENT
• Approximately half to two thirds of patients with major depression will improve with antidepressant
treatment when treated with an adequate dose of any antidepressant after eight weeks of treatment.
• Even without therapy, the majority of patients with major depression recover within 6-12 months.
• Suicidality remains a major risk factor in patients with major depression and 10-15% of patients with severe
major depression eventually commit suicide, with the risk of suicide increasing after the initial lifting of
depression and return of energy.
• The use of antidepressant medication approximately doubles the chance that a depressed patient will recover
within two to four months.
• The main causes of failed antidepressant trials are due to the use of inadequate dosage and/or an inadequate
time for the medication to take effect.
• Antidepressants should be maintained at their maximum recommended dosage with minimum adverse
side-effects and should be tried for at least four to six weeks before evaluating effectiveness.
• Discontinuation of Antidepressant treatment during the first 30 days of treatment is more common among
racial minorities, and economically and educationally disadvantaged populations.
• In general, most antidepressants increase synaptic serotonin, norepinephrine, or dopamine principally by
inhibiting their reuptake and metabolism. These first messengers then trigger a signal transduction cascade.
• Lithium, thyroid hormone (T3) and other agents may be used to augment the effect of antidepressants.
• The combination of antipsychotics and antidepressants can be used in patients who have depression with
psychotic features.
• Electroconvulsive therapy (ECT) is the most efficacious treatment for subtypes of severe depression and/or
depression refractory to pharmacotherapy (see chapter on “Somatic Treatments”).
• Classes of Antidepressants include: selective serotonin reuptake inhibitors (SSRIs), serotoninnorepinephrine reuptake inhibitors (SNRIs), heterocyclic and tricyclic antidepressants (TCAs),
monoamine oxidase inhibitors (MAOIs), norepinephrine-reuptake inhibitors (NRIs), norepinephrinedopamine reuptake inhibitors (NDRIs), atypical antidepressants, and stimulants. (Atypical antipsychotics
and anticonvulsants have antidepressant effects, commonly used in combination with antidepressants)
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Standard Dosage
Range (mg/day)

5-80
25-150

Paroxetine (Paxil)
Serteraline
(Zoloft)
Fluvoxamine (Luvox)
Citalopram (Celexa)
Escitalopram (Lexapro)

84 (7-10 days for
active metabolite)
15-20
24 (2-4 days for
active metabolite)
16-20
35
30

Half Life (hr)

10-50
11-40
20-50
5-25

25-300
25-300
50-250
25-150

50-200
40-120

5 (10 hrs for
active metabolite)
8
12

75-375

None/Mild
None/Mild
Mild
Moderate

Moderate
Mild/Moderate

Moderate

Moderate
Moderate
Moderate

Moderate
Moderate

Moderate

Insomnia &
Agitation

Severe
Severe
Severe
Moderate

None/Mild
Mild

None/Mild

None/Mild
None/Mild
None/Mild

None/Mild
None/Mild

None/Mild

Sedation

18-44
21-25

25-150
50-200

Adapted from Mann, J., NEJM, 2005

Bupropion (Wellbuterin)
Mirtazapine (Remeron)
Nefazodone (Serzone)
Trazodone (Desyrel)

Mixed-Action and Newer Agents

Phenelzine (Nardil)
Tranylcypromine (Parnate)
Isocarboxazid (Marplan)
Selegiline (Eldepryl)
Moclobemide (Manerix)
75-450
7.5-60
50-600
50-600

7.5-60
5-60
20-60
5-10
300-600
4-24
20-40
2-18
4-9

1.5-4
4.4-8
2.5
2
1.5-4

12-24

25-300

Monoamine Oxidase Inhibitors (MAOIs)

Desipramine (Norpramine)
Nortriptyline
(Pamelor)
Maprotiline (Ludiomil)

Moderate
None/Mild
None/Mild
None/Mild

Moderate
Moderate
Moderate
Mild
Mild

Mild
Moderate

Moderate

None/Mild
Severe
Moderate
Severe

Mild
Mild
None/Mild
None/Mild
None/Mild

Mild
None/Mild

None/Mild

Secondary amine TCAs and Tetracyclic Antidepressants [Nonselective Norepinephrine –Reuptake Inhibitors]

Venlafaxine
(Effexor)
Milnacipran (Ixel)
Duloxetine (Cymbalta)
Tricyclic Antidepressants (TCAs)
Tertiary Amine TCA’s
Amitrptyline (Elavil)
Dothiepin (Dothep)
Clomipramine (Anafranil)
Imipramine (Tofranil)

Selective Serotonin Norepinephrine-Reuptake Inhibitors (SNRIs)

25-300
20-40
10-20

5-40

Fluoxetine (Prozac)

Selective Serotonin-Reuptake Inhibitors (SSRIs)

Functional Classification
Generic (trade name)

Table 1. Classification, Dose Range, and Side Effects of Antidepressants

None/Mild
Mild
Mild
Mild

Moderate
Moderate
Moderate
Mild
Mild

Mild
Mild

Moderate

Moderate
Moderate
Moderate
Moderate

None/Mild
None/Mild

None/Mild

None/Mild
None/Mild
None/Mild

None/Mild
None/Mild

None/Mild

Hypotension

Mild
None/Mild
Mild
None/Mild

Mild
Mild
Mild
Mild
Mild

Mild
Mild

Mild

Severe
Moderate
Moderate
Moderate

None/Mild
Mild

None/Mild

None/Mild
None/Mild
None/Mild

Mild
None/Mild

None/Mild

Anticholinergic
Effects

None/Mild
None/Mild
Mild
Mild

Mild
Mild
Mild
Mild
Mild

None/Mild
None/Mild

None/Mild

None/Mild
None/Mild
Mild
None/Mild

Moderate
None/Mild

Moderate

Moderate
Moderate
Moderate

Moderate
Moderate

Moderate

Nausea &
GI effects

None/Mild
None/Mild
None/Mild
Moderate

Moderate
Moderate
Moderate
Mild
None/Mild

Mild
Mild

Mild

Mild
Mild
Mild
Mild

Moderate
None/Mild

Moderate

Moderate
Moderate
Moderate

Moderate
Moderate

Moderate

Sexual
Dysfunction

None/Mild
Severe
Mild
Mild

Mild
Mild
Moderate
Mild
None/Mild

Mild
Moderate

Mild

Moderate
Moderate
Moderate
Moderate

None/Mild
None/Mild

None/Mild

Mild
Mild
Mild

Moderate
Mild

Mild

Weight Gain

ALGORITHM FOR ACUTE TREATMENT OF MAJOR DEPRESSION
Figure 1. NEED TITTLE
Initiate Antidepressant Treatment
-SSRI, SNRI, TCA, MAOI, Other

Partial or No Response (after 4-6 weeks of Tx and
adequate dosage):
-Reassess diagnosis
-Increase dosage for treatment optimization

Switch to second antidepressant from the same or
a different pharmacological class

Inadequate Response

Augment Tx:
1. Li
3. Atypical anti-psychotic
2. Thyroid hormone
4. Lamotrigine

Combine two antidepressants:
-from two different pharmacologic classes

Consider ECT: esp in: very depressed, not eating,
catatonia, psychotic delusions, pregnancy

Consider Psychotherapy at any time
during treatment
(Adapted from Mann, J., NEJM, 2005)

MECHANISM OF ANTIDEPRESSANT ACTION
The mechanism of action of antidepressant medications is not precisely known, however, the “monoamine
hypothesis” of depression stems in part from the serotonin, norepinephrine and dopamine augmenting effects of
antidepressants. The modulation of serotonin, which is produced in the neurons of the raphe nuclei of the brainstem, appears to be central to both the pathology and treatment of depression. The most effective antidepressant
medications appear to increase synaptic levels of monoamines, produce down-regulation of post-synaptic receptors
and trigger a cascade of signal transduction effects that ultimately lead to changes in gene regulation.

CLASSES OF ANTIDEPRESSANTS
SSRIs
Mechanism of Action
• Inhibit the reuptake of serotonin (5-hydroxytryptamine or 5-HT) at the synaptic cleft.
• Initial high levels of serotonin in the cleft will not only activate post-synaptic receptors, but also stimulate
autoreceptors of pre-synaptic cells thereby transiently decreasing serotonin production. Neurons adapt to
the high levels of serotonin in the cleft and autoreceptors are down regulated thereby not interfering with
serotonin production.
• Changes in receptor adaptation and signal transduction in animal models occur over several weeks and it is
believed that these effects mediate the effects of antidepressants and explain why SSRIs take several weeks to
take effect.
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Primary Indication
• The primary indication of SSRIs is for the treatment of major depressive disorder (MDD).
• All SSRIs are equally effective in treating depression, although they differ enough from one another that
failure to respond to one SSRI doesn’t predict failure to a different SSRI.
• SSRIs are the safest alternative in depressed patients with cardio-vascular comorbidities.

Indications for Specific SSRIs
• Fluoxetine is approved by the FDA for treatment of:
- Acute major depressive disorder (adult and pediatric), recurrent major depressive disorder, bulimia nervosa,
obsessive-compulsive disorder, panic disorder, and premenstrual dysphoric disorder.
- Also effective in treating MDD associated with alcoholism, MDD associated with diabetes, seasonal affective
disorder, posttraumatic stress disorder, obesity, hot flashes, migraine headache prophylaxis, and
fibromyalgia.
• Paroxetine is approved by the FDA for treatment of:
- Acute major depressive disorder (adults), generalized anxiety disorder, and social phobia.
- Also effective in treatment of interferon-induced major depressive disorder, diabetic neuropathy, premature
ejaculation, and vasovagal syncope.
• Sertraline is approved by the FDA for treatment of:
- Acute major depressive disorder (adults), recurrent major depressive disorder, obsessive-compulsive
disorder, panic disorder, posttraumatic stress disorder, premenstrual dysphoric disorder, and social anxiety
disorder.
- Also effective in treating major depressive disorder s/p myocardial infarction, major depressive disorder
associated with Alzheimer’s dementia, generalized anxiety disorder, premature ejaculation, and dysthymic
disorder.
• Fluvoxamine is approved by the FDA for treatment of:
- Obsessive-compulsive disorder (adult and pediatric).
• Citalopram is approved by the FDA for treatment of:
- Acute major depressive disorder (adults).
- Also effective in the treatment of panic disorder, prostatodynia, and social anxiety disorder, MDD associated
with stroke, diabetic neuropathy, dysthymic disorder, headache, impulsive aggressive disorder, obsessivecompulsive disorder, panic disorder, pathologic crying, pathologic gambling, posttraumatic stress disorder,
and premenstrual dysphoria syndrome.
• Escitalopram is approved by the FDA for treatment of:
- Acute major depressive disorder (adults) and generalized anxiety disorder.
Adverse Effects
(See also Table 1)
Gastrointestinal GI: Side effects are common, including nausea, cramping, diarrhea, bloating, and abdominal
pain.
Cardiovascular: May cause bradycardia, normalization of heart rate variability, which may be cardio-protective.
Sertraline is extensively studied (SADHEART trial, Glassman et al., JAMA, 2002), proven effective post-myocardial
infarction and with unstable angina, with no adverse cardiac effects.
Hematologic: Decrease platelet aggregation, increase bleeding time, leading to easy bruising and risk for GI and
other bleeding, particularly in the elderly and when combined with non-steroidal anti-inflammatory drugs
(NSAIDS).
Hepatic: Mild AST, ALT elevations possible.
Metabolic and Endocrine: In women, galactorrhea may occur with some SSRIs, due to serotonin down-regulation of dopamine.
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Sexual Dysfunction: Decreased libido and delayed or no orgasm are the most common. Dysfunction of erection or engorgement less common.
Neurologic and Neuropsychiatric: SSRIs can cause neuromuscular irritability and extrapyramidal side effects,
including worsening of tremor and rigidity in disorders such as Parkinson’s Disease and spastic cerebral palsy.
Serotonin Syndrome, caused by excessive serotonin (such as occurs with high-dose SSRIs or SSRIs in combination
with MAOI’s and other agents that potentiate serotonin function), is characterized by delirium, neuromuscular irritability, seizures and autonomic instability signs. It is clinically similar to NMS. Apathy or blunting of emotions is
also common with long-term SSRI treatment, thought to be secondary to dopamine down-regulation with SSRIs.
Pregnancy and Lactation: (see section on Women’s Mental Health and Reproductive Psychiatry). SSRIs are all
Pregnancy class C medications. Recent evidence suggests risk for persistent pulmonary hypertension in neonates
when mothers treated in third trimester with SSRIs. Paroxetine recently implicated in an increased risk of birth
defects, particularly VSDs and ASDs. SSRIs may cause discontinuation symptoms in neonates. SSRIs all pass into
breast milk, though levels of sertraline in nursing infants minimal.
Overdose: Generally safe in overdose.
Suicide Risk: SSRIs now carry “black box” warnings due to increased risk of suicidality (suicidal thinking and
behavior) in children and adolescents being treated with these agents. An FDA review of a total of 24 antidepressant
trials involving over 4400 patients showed a greater risk of suicidality during the first months of treatment in those
receiving antidepressants. The average risk of such events on drug was 4%, twice the placebo risk of 2%. Other relevant recommendations from the FDA include:
• Anyone considering the use of an antidepressant in a child or adolescent for any clinical use must balance the
risk of increased suicidality with the clinical need.
• Patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual
changes in behavior.
• Families and caregivers should be advised to closely observe the patient and to communicate with the
prescriber.

TCAs
Mechanism of Action
• TCAs block the Norepinephrine and 5-HT presynaptic transporter sites and to a lesser extent the Dopamine
reuptake transporter.
• Clomipramine is predominantly a 5-HT reuptake inhibitor, whereas desipramine, nortriptyline, and
protriptyline are predominantly NE reuptake inhibitors and amitriptyline, doxepin, imipramine, and
trimipramine are largely equal in inhibiting both the NE and the 5-HT reuptake mechanism.
Indications
• The primary indication of TCAs, except clomipramine, is for the treatment of Major Depressive Disorder.
• Clomipramine is FDA approved for the treatment of obsessive-compulsive disorder.
Special Indications
• Panic disorder, social phobias, post traumatic stress disorder, reducing binging and purging in bulimia
nervosa, refractory pain syndromes (diabetic neuropathy, fibromyalgia, fibrositis, rheumatoid arthritis,
central pain).
• Effective in the treatment of premature ejaculation.
• Imipramine and clomipramine are effective in treating catapleptic episodes associated with narcolepsy.
Adverse Effects
Anticholinergic: Blurred vision, urinary retention, constipation, dry mouth are not dose dependent. The estimation of anticholinergic potency are as follows: amitryptyline > trimipramine > doxepin > imipramine >
desipramine > nortriptyline.
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Cardiovascular: Orthostatic hypotension is the most serious complication, due to anti a-1 adrenergic effects.
TCAs are class I (quinidine-like) antiarrhythmics, causing decreased conduction through the A-V node and resulting in Q-T prologation.
• In patients with preexisting first degree atrioventricular (AV) block there is a risk of complete block and
therefore ECG monitoring is required in this patient population.
• TCAs should not be used in patients with cardiovascular disease and should be avoided in post-MI patients
in whom TCAs are associated with increased risk of morbidity and mortality.
Dermatologic: Cutaneous vasculitis, urticaria, and photosensitivity.
Hematologic: Benign eosinophilia and leucopenia transiently occur in the first few weeks of therapy.
Agranulocytosis, although rare, is a medical emergency and can be fatal so CBC should be monitored in this patient
group.
Hepatic: AST, ALT, Alk Phos, or even bilirubin elevations are not uncommon. AST or ALT elevation with values
three times the upper limit of normal are worrisome and the TCA should be discontinued.
Metabolic and Endocrine: In women, Galactorrhea and amenorrhea, which are dose dependent, have been
reported. Weight gain has also been reported with TCAs.
Neurologic and Psychiatric: Acute delirium, as a result of TCA’s anticholinergic properties, has been reported
and can be treated with physostigmine. This effect is more common in the elderly and African Americans and is
dose dependent (more common in higher doses). A fine resting tremor has also been observed. TCA’s can lower the
seizure threshold. Switching from depressed to manic or hypomanic states has been reported in bipolar depressed
patients.
Sexual Dysfunction: Primarily erectile dysfunction. Imipramine > desipramine > clomipramine > amitriptyline > protriptyline in decending order cause disturbances in sexual function.
Pregnancy and Lactation: (see Chapter on Women’s Mental Health and Reproductive Psychiatry) Imipramine,
amitriptyline, nortriptyline associated with congenital anomalies (category D).
Overdose: The most serious consequence of TCA overdose relate to their cardiovascular effects.
Superventricular tachycardia, multifocal PVCs, ventricular tachycardia, flutter, or fibrillation can result in severe
hypotension or shock. ECG abnormalities in overdose include prolonged PR interval, widened QRS complex, QT
prologation, T-wave flattening or inversion, ST-segment depression, right bindle branch block, complete heart block,
or cardiac standstill. Treatment for overdose includes alkalization of serum in addition to cardiac monitoring and
ventilatory and pressor support.
• The combined use of TCA and MAOIs are counter indicated.

SNRIs and Newer Mixed Agents
Mechanism of Action
• SNRIs block monoamine transporters more selectively than TCAs and without the potential adverse
cardiac-conduction effects of TCAs.
• Duloxetine and Venlafaxine block both serotonin and norepinephrine reuptake. At lower dosages (i.e., <200
mg/day) Venlafaxine appears to be more selective for serotonin transporter; at higher dosages, the
noradrenergic effects become more prominent.
• Bupropion blocks the reuptake of norepinephrine and dopamine. It has no serotonergic activity. It is
indicated for the treatment of major depressive disorder and smoking cessation.
Indications
• In some studies, Venlafaxine appears to demonstrate superior efficacy and higher rates of remission in
severe depression as compared to SSRIs such as fluoxetine or TCAs. This is still an open issue.
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• Venlafaxine and duloxetine are effective for the treatment of chronic pain, diabetic neuropathy, and pain
occurring as part of primary or secondary depression. Only Duloxetine has FDA approval for diabetic
peripheral neuropathy.
• Buproprion is associated with less nausea, diarrhea, somnolence, and sexual dysfunction than SSRIs.
Bupropion is also effective in treating SSRI-induced sexual dysfunction. In fact, cases of spontaneous and
prolonged orgasm on buproprion have been documented in the literature.
Adverse Effects
Generally, side effects are similar to those associated with SSRIs.
• Dose dependent increases in systolic and diastolic blood pressure have been reported in patients on
venlafaxine, and bupropion.
• Buproprion has been documented to cause seizures at doses >400mg/day. It should not be used in patients
with epilepsy and bulimia.

MAOIs
Mechanism of Action
• MAOIs inhibit the activity of monoamine oxidase, an enzyme that breaks down cathecholamine and
indolamine neurotransmitters, thereby increasing levels of neurepinephrine, dopamine, and serotonin
neurotransmitters.
• Earlier MAOIs inhibited monoamine oxidase irreversibly but newer MAOIs such as moclobemide are
reversible inhibitors.
• Two isoforms of MAO have been identified—these are: MAO-A & MAO-B. MAO-A preferentially degrades
serotonin, melatonin, epinephrine, and norepinephrine whereas MAO-B preferentially targets
phenylethylamine, dopamine, and benzylamine. Newer MAOIs like selegiline (Ensem patch) target the
MAO-B more selectively. Drugs that block gastrointestinal MAO-A, like the earlier MAOIs, require patients
to be on a low tyramine diet because dietary tyramine is metabolized by MAO-A in the gut.
Indications
• MAOIs are indicated for typical Major Depressive Disorder and atypical depression. They are preferentially
more effective than TCAs in the treatment of atypical depression.
Special Indications
• Panic disorder, social phobia, neurodermatitis, treatment resistant narcolepsy, migrane headaches, and
idiopathic hypotension.
Adverse Effects
Allergic: Maculopopular rashes, red-green blindness with optic atrophy (rare).
Cardiovascular: Conduction abnormalities such as QTc interval shortening, orthostatic hypotension.
Hypertensive Crisis: The consumption of foods or other products containing pressor amines or sympathomemetic agents together with MAOIs have resulted in critical hyperadrenergic states characterized by elevations in
both systolic and diastolic blood pressures with potentially dire consequences such as fatal strokes, cardiac arrhythmias, or cardiac failure. Tyramine containing foods, most commonly aged cheeses and red wine, are frequently
implicated in this complication. Other amines or precursors to amines such as histamine, dopamine, levodopa, and
tyrosine may also be implicated. Sympathomimetics such as amphetamines and ephedrine and TCAs can also precipitate this complication when used in conjunction with MAOIs.
• Patients on MAOIs should therefore be on tyramine-restricted diets and avoid over the counter remedies
that may contain sympathomimetics such as phenylephrine based cold remedies. In addition, a washout of
at least 14 days should be in effect when switching MAOIs to prevent potential hypertensive crises.

Psychiatry

|

Treatment of Psychiatric Disorders | Antidepressant Medications

217

Neurologic: Peripheral sensory neuropathy—probably as a result of pyridoxine deficiency secondary to
phenelzine. Other effects include ataxia, hyperacusis, hyperritability, muscle tension, myoclonic jerks, carple tunnel
syndrome, and in its most severe form seizures, coma, or death. Anorgasmia and impotence have been reported with
phenelzine. Phenelzine and tranylcypromine have been associated with daytime drowsiness.
Psychiatric: Similar to TCAs “flipping” from depression to mania or hypomania can occur with MAOIs.
Overdose: Potentially fatal, symptoms may not be evident for 6 to 12 hrs. after ingestion. These include flushing, diaphoresis, tachycardia, hypertension, mental confusion, increased deep tendon reflexes, involuntary movements, seizure.
Teratogenicity and Excretion in Breast Milk: FDA category C, MAOIs are counterindicated during pregnancy
and tranylcypromine is known to be excreted in breast milk.
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